chrisvoncsefalvay/vaers-outcomes huggingface dataset:
11/18/03, swelling and redness left arm. 11/20/03 hives. Went to see doctor and was given steroids and Zyrtec. 11/22/03 hives gone.
On 16JAN92 pt mom reported rxn to prev immun 16OT91; awoke to find pt seizing (total of 2 seizures); t102-103 ax; pts father called hosp & reported fever, but not the sz activity; MD determined parents were not giving adequate dose of APAP;
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 39-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 20Nov2022 at 12:15 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 39 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), first regimen (Batch/Lot number: unknown) at single (dose 2, single) and second regimen (Batch/Lot number: unknown) at single (dose 1, single) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: PORTIA-28 oral taken for contraception, start date: 01Dec2022, stop date: 30Jan2023. Past drug history included: Codeine, reaction(s): "known allergies: Codeine", notes: known allergies: Codeine.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jan2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19.   Clinical information: At home test rapid test for COVID was positive on 06Jan2023. Took Paxlovid from 06Jan2023-11Jan2023. Tested negative on 14Jan2023 and 15Jan2023 (at home rapid test).   The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Approx. 6-7 hours after receiving yellow fever vaccine, client noted "hives" on lower legs with intense itching. Benadryl tab taken @ hs. Next day noted increase in number of hives on legs & also around injection site on arm. To dermatologist 5/26 who felt hives do to yellow fever vaccine. 5/31, per mother, hives fading in color, but not in number.  Hives have remained localized on legs between ankles & knees.  Itching has decreased, using topical cream from dermatologist.
After 7 days, feeling pain in both foots. Especially at the heels, finger joints and ankle. Mostly in right foot. The pain increase during laying  or sitting, but it decreases while walking. No swelling, but there is redness and itchiness at right foot. Sometimes  my right leg aches.
Pt had redness starting on 12/4  on the right arm. Pt called the pharmacy on 12/6 because redness was not going away. pt was instructed to go to minor emergency clinic to get it checked out. Pt went to minor emergency clinic on 12/7.  Dr said she had cellulitis and pt received a rx for cephalexin. checked with pt on 12/15 pt said infection had gone away.
headache started 2 hours after first vaccine was given; didn't take any pain reliever for it; headache went away on its own during the night.  Left arm sore at the injection site for about 3 days (took Tylenol 48 hrs after getting the vaccine to relieve pain in arm).  On Monday morning 2/15/21, lymph node above left clavicle bone hurt to touch (pea size), and the left trapezius muscle started hurting whenever I touch it and feels hard/swollen.  Don't feel  any swollen lymph nodes yet under left arm.  Taking Tylenol when needed for inflammation.
Patient recieved 2nd Moderna Covid-19 dose on 5/8/2021 and approximately 1 month later experienced itching/tingling in his hands and feet.  Patient had a full physical in July 2021 and all test, bloodwork, bloodpressure came back "perfect".
This spontaneous report as received from a nurse refers to a 10 months 22 days old female patient. No concurrent condition, medical history or allergy/drug reactions were reported. On an unspecified date, the patient was vaccinated with improperly stored (exposed to 52.8 Fahrenheit for a total of 105 hours) ROTATEQ lot # K016313, exp. date: 31-MAY-2016 and lot # K011663, exp. date: 20-MAY-2016 (dose and strength unspecified) oral. No concomitant medications were reported. No adverse experiences have been reported so far. There were no product quality complaints (PQC) involved. No additional information was provided. All telephone attempts to obtain follow-up information had been unsuccessful. This is one of several reports received from the same reporter. Additional information is not expected, no contact details were provided.
Heart palpitations and chest pain. Had to go into the doctor and they thought I was having a panic attack and I didn?t have money for a cardiogram. Blood pressure was extremely high.
Pericarditis was considered medically important (OMIC). A mother reported that her 18 year old son received a dose of Flumist solution on 10/11/03. The pt's concurrent illnesses include an unspecified "nerve" disorder, allergies, and GERD. The pt also has a history of pericarditis and urinary tract problems as a result of a car accident in March 2003. Indication for Flumist was immunization. Product was administered on 10/11/03. Dose regimen was one dose. Concomitant therapy included Paxil, Detorl LA, Protonix, guaifenesin, Advair, and Clarinex. On 10/14/03, the reporter's son experienced sores in his mouth (stomatitis). The pt returned to his physician on 10/15/03 and received Valtrax to treat the mouth sores; however, it was reported "the Valtrex did not help." On 10/20/03, he developed fever of 102-104 deg F and chest pain. The mother believed that her son's pericarditis (condition aggravated) might have returned as a result of receiving Flumist. Her son had not returned to his physician since experiencing the fever and chest pain. All events were unresolved at the time of this report. No additional info was available at the time of this report.  The medical records received on 11/20/03 state pharengitis.
Patient has still never contracted COVID-19, although he has tested many times for school. He received vaccinations as soon as they became available to him in April 2021, with the second dose in May 2021. He received a booster in Nov 2021 and that led to the first adverse reaction. In Feb 2022, he had severe chest pain and he tried to rest it off but finally called home and asked advice. Since my husband had recently had an adverse reaction which led to multiple pulmonary emboli (still not having had COVID), I suggested he go to the ER and ask them to scan and see if he also had those. He went to the local Regional Medical Center and they determined he had multiple pulmonary emboli. They prescribed a blood thi
Tired; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Tired) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included FISH OIL for an unknown indication.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FATIGUE (Tired). At the time of the report, FATIGUE (Tired) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: (Inconclusive) temperature of 98.7F, lowest 98F for 13 days.         The treatment information was not provided.
Left thigh with minimal erythema and swelling starting 10/21/22 at or around 3:30pm.
My wife has lost all her hair; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (dose 1, unknown manufacturer), for COVID-19 immunization; Covid-19 vaccine (dose 2, unknown manufacturer), for COVID-19 immunization; Covid-19 vaccine (dose 3, unknown manufacturer), for COVID-19 immunization. The following information was reported: ALOPECIA TOTALIS (non-serious), outcome "unknown", described as "My wife has lost all her hair". The event "my wife has lost all her hair" required physician office visit. Additional information: the patient specified that his wife has lost all her hair. She started just after she got the fourth Covid shot. First part of November she had a full head of hair. Now nothing. They've seen doctors with no answers.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
2 weeks post vax, pt began shaking. Pt developed a large, red, raised and itchy area near injection site. Pt was seen by a physician and was prescribed Triamolone to relieve itching which helped some after several applications.
Patient was given a MENACTRA shot, less than 5 minutes later she collapse, but still conscious. Called paramedics to check on patient.
Pt had a seizure 2:00 a.m. the following morning. Went to Emergency room for evaluation.  Did not require hospitalization.
Had +covid in beginning of October 2020, got the plasma, At 1 am 1/13/21, body sores, all muscles,  sore joints, fingers swollen, head, neck, ribs, legs, arms.
Chest pains while working out since receiving the vaccine. Ultimately, two blood clots were formed and caused a cardiac arrest May 25th, 2021.
This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (discomfort at the injection site), INJECTION SITE PAIN (tenderness), VACCINATION SITE RASH (big red rash, near the site inject), PAIN IN EXTREMITY (COVID arm) and VACCINATION SITE PRURITUS (itchy) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE PAIN (discomfort at the injection site), INJECTION SITE PAIN (tenderness), VACCINATION SITE RASH (big red rash, near the site inject), PAIN IN EXTREMITY (COVID arm) and VACCINATION SITE PRURITUS (itchy). At the time of the report, INJECTION SITE PAIN (discomfort at the injection site), INJECTION SITE PAIN (tenderness), VACCINATION SITE RASH (big red rash, near the site inject), PAIN IN EXTREMITY (COVID arm) and VACCINATION SITE PRURITUS (itchy) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No relevant concomitant medications were reported. No treatment information was provided.
Unusual tingling and sensitivity on skin, of right side of torso (stomach, side and back).  Not painful, but sensitive.  No rash, or visible difference from skin on left side of torso .  Symptoms are mild-not severe.
Feeling lousy today; She can't think and feels lethargic; Right arm is hurting; Can't move her right arm good; Dizziness; Nausea; Given full dose instead of half dose (booster); This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Feeling lousy today), LETHARGY (She can't think and feels lethargic), PAIN IN EXTREMITY (Right arm is hurting), INJECTED LIMB MOBILITY DECREASED (Can't move her right arm good) and DIZZINESS (Dizziness) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037F21A, 027170A and 013M2ZA) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes, Blood pressure high and Allergy to antibiotic. Concomitant products included INSULIN, PARACETAMOL (TYLENOL) and GABAPENTIN for an unknown indication.   On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INCORRECT DOSE ADMINISTERED (Given full dose instead of half dose (booster)). On 21-Oct-2021, the patient experienced VACCINATION COMPLICATION (Feeling lousy today), LETHARGY (She can't think and feels lethargic), PAIN IN EXTREMITY (Right arm is hurting), INJECTED LIMB MOBILITY DECREASED (Can't move her right arm good), DIZZINESS (Dizziness) and NAUSEA (Nausea). On 20-Oct-2021, INCORRECT DOSE ADMINISTERED (Given full dose instead of half dose (booster)) had resolved. At the time of the report, VACCINATION COMPLICATION (Feeling lousy today), LETHARGY (She can't think and feels lethargic), PAIN IN EXTREMITY (Right arm is hurting), INJECTED LIMB MOBILITY DECREASED (Can't move her right arm good), DIZZINESS (Dizziness) and NAUSEA (Nausea) outcome was unknown.      Concomitant medications also included blood pressure medication.  No treatment information was provided.
This is a spontaneous report from a contactable physician via a Pfizer sales representative. A 66-year-old female patient started to receive PREVNAR 13, via an unspecified route of administration, single dose on Nov2017 for immunization. The patient medical history was not reported. The patient's concomitant medications includes unspecified other vaccinations. On an unspecified date, the patient experienced pain and swelling at the injection site and there was more pain than expected. The outcome of the events was unknown. No follow-up attempts are possible. No further information is expected.
This spontaneous case reported by a consumer, describes the occurrence of inappropriate schedule of product administration (second dose after 8 weeks) and herpes zoster (had a bout of shingles) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 013M20A) for COVID-19 vaccination. No medical history reported. On Mar 1, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On an unknown date, patient experienced inappropriate schedule of product administration (second dose after 8 weeks) and herpes zoster (had a bout of shingles). At the time of the report, inappropriate schedule of product administration (second dose after 8 weeks) and herpes zoster (had a bout of shingles) outcome: unknown/not provided. The action taken with mRNA-1273 (Moderna COVID-19  vaccine), intramuscular: unknown. No concomitant medication or treatment information provided.
Vaccinated with Varivax on 09/04/01. Reported dx chickenpox 06/25/03.
This spontaneous report as received from a medical assistant refers to a patient of unknown demographics. On an unknown date in August 2012, the patient was vaccinated with a dose of improperly stored GARDASIL (Lot number, expiry date, route and dose were not reported). The medical assistant reported that the vaccine was exposed to temperature of 26 F (Fahrenheit) for a total of 135 hours. No adverse effects reported. Follow-up received. Medical assistant stated that other 104 children received GARDASIL. Follow up information has been received from the medical assistant regarding an unknown age and gender, patient with no pertinent medical history reported. The medical assistant reported that on 21-AUG-2012 the patient was vaccinated with GARDASIL (lot number and expiration date not reported) (intramuscular on the left arm, dose not reported). Concomitant therapies included an Hepatitis A vaccine (manufacturer unknown) administered on 21-AUG-2012 (lot number and expiration date not reported) (intramuscular on the right arm, dose not reported). It was reported that the patient did not seek medical attention. This is one of the several reports from the same source. Additional information is not expected.
Woke up with left eye pink; left eye has a little pinch of fluid; This spontaneous case was reported by a consumer and describes the occurrence of CONJUNCTIVITIS (Woke up with left eye pink) and LACRIMATION INCREASED (left eye has a little pinch of fluid) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Mar-2021, the patient experienced CONJUNCTIVITIS (Woke up with left eye pink) and LACRIMATION INCREASED (left eye has a little pinch of fluid). At the time of the report, CONJUNCTIVITIS (Woke up with left eye pink) and LACRIMATION INCREASED (left eye has a little pinch of fluid) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information not provided. List of concomitant medication were not given.
headache; nausea; fatigue; diarrhea; chills; joint pain; muscle pain; vomiting; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea), CHILLS (chills), ARTHRALGIA (joint pain), MYALGIA (muscle pain) and VOMITING (vomiting) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031.20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.     On 20-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, the patient experienced DIARRHOEA (diarrhea), CHILLS (chills), ARTHRALGIA (joint pain), MYALGIA (muscle pain) and VOMITING (vomiting). On an unknown date, the patient experienced HEADACHE (headache), NAUSEA (nausea) and FATIGUE (fatigue). On 22-Feb-2021, ARTHRALGIA (joint pain), MYALGIA (muscle pain) and VOMITING (vomiting) had resolved. At the time of the report, DIARRHOEA (diarrhea), CHILLS (chills), HEADACHE (headache), NAUSEA (nausea) and FATIGUE (fatigue) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
No Adverse Event; A dose of Moderna Covid-19 vaccine (Monovalent) that was expired was given on 12Mar2023. It actually expired on 11Mar2023.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (A dose of Moderna Covid-19 vaccine (Monovalent) that was expired was given on 12Mar2023. It actually expired on 11Mar2023.) and NO ADVERSE EVENT (No Adverse Event) in a 17-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 074B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Mar-2023, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (A dose of Moderna Covid-19 vaccine (Monovalent) that was expired was given on 12Mar2023. It actually expired on 11Mar2023.). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse Event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (A dose of Moderna Covid-19 vaccine (Monovalent) that was expired was given on 12Mar2023. It actually expired on 11Mar2023.) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (A dose of Moderna Covid-19 vaccine (Monovalent) that was expired was given on 12Mar2023. It actually expired on 11Mar2023.).    No concomitant medications was provided. No treatment medications was provided.
my face and neck felt very hot with swelling; my face and neck felt very hot with swelling; my face and neck felt very hot with swelling; face broke out in rash; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09Sep2022 as dose 4 (booster), single (Lot number: GH9694) at the age of 69 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Breast cancer", start date: 2009 (unspecified if ongoing); "thymoma", start date: 2022 (unspecified if ongoing); "hysterectomy" (unspecified if ongoing); "kidney stone" (unspecified if ongoing); "gall bladder removal" (unspecified if ongoing); "Known allergies: Antibiotics: sulfa" (unspecified if ongoing); "Known allergies: Antibiotics: macrolides" (unspecified if ongoing); "Known allergies: Antibiotics: penicillins" (unspecified if ongoing). Concomitant medication(s) included: ESCITALOPRAM; VITAMIN D 2000 DUO. Past drug history included: Clindamycin, reaction(s): "Known allergies: Antibiotics: clindamycin". Vaccination history included: Covid-19 vaccine (Dose 1; Unknown manufacturer), for COVID-19 Immunization; Covid-19 vaccine (Dose 2; Unknown manufacturer), for COVID-19 Immunization; Covid-19 vaccine (Dose 3 (booster); Unknown manufacturer), for COVID-19 Immunization. The following information was reported: RASH (non-serious) with onset 09Sep2022 at 20:00, outcome "recovered", described as "face broke out in rash"; FEELING HOT (non-serious), SWELLING FACE (non-serious), SWELLING (non-serious) all with onset 09Sep2022 at 20:00, outcome "recovered" and all described as "my face and neck felt very hot with swelling". Therapeutic measures were taken as a result of feeling hot, swelling face, swelling, rash. Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination nor was tested for COVID-19 since vaccination. Within 2 to 3 hours of vaccination (as reported), patient's face and neck felt very hot with swelling and her face broke out in rash. Took 50 mg of diphenhydramine (BENADRYL).  Follow-up attempts are completed. No further information is expected.
Patient walked away and a minute or so later came back and reported she was dizzy.  She sat down and became flushed.  5-10 minutes later she said she was short of breath.  She did not have any wheezy breath sounds or signs of constriction or localized reactions at injection sites.   MR received from hospital. PMH: 75 yr. old with hx. of depression osteoarthritis, CAD, reflux and urinary stress incontinence.  Within 5-10 minutes of receiving pneumovax, pt. became dizzy, flushed, short of breath, and experienced some chest pressure and muscle spasm.  Evaluated in ER where she was stable. PE was normal.  Given cardiac hx. she was admitted for serial cardiac enzymes and observation o/n. She remained stable with no c/o  chest pain or SOB.  Discharged next day.  Assessment: Allergic reaction to Pneumovax.
Period came early, a very strong blood flow, a lot of clots, different colour and consistency.